Recombinant dimeric envelope vaccine against flaviviral infection

Abstract

The present invention discloses and claims vaccines containing, as an active ingredient, a secreted recombinantly produced dimeric form of truncated flaviviral envelope protein. The vaccines are capable of eliciting the production of neutralizing antibodies against flaviviruses. The dimeric forms of truncated flaviviral envelope protein are formed 1) by directly linking two tandem copies of 80% E in a head to tail fashion via a flexible tether; 2) via the formation of a leucine zipper domain through the homodimeric association of two leucine zipper helices each fused to the carboxy terminus of an 80% E molecule; or 3) via the formation of a non-covalently associated four-helix bundle domain formed upon association of two helix-turn-helix moieties each attached to the carboxy terminus of an 80% E molecule. All products are expressed as a polyprotein including prM and the modified 80% E products are secreted from Drosophila melanogaster Schneider 2 cells using the human tissue plasminogen activator secretion signal sequence (tPA L ). Secreted products are generally more easily purified than those expressed intracellularly, facilitating vaccine production. One embodiment of the present invention is directed to a vaccine for protection of a subject against infection by dengue virus. The vaccine contains, as active ingredient, the dimeric form of truncated envelope protein of a dengue virus serotype. The dimeric truncated E is secreted as a recombinantly produced protein from eucaryotic cells. The vaccine may further contain portions of additional dengue virus serotype dimeric E proteins similarly produced. Another embodiment of the present invention is directed to methods to utilize the dimeric form of truncated dengue envelope protein for diagnosis of infection in individuals at risk for the disease. The diagnostic contains, as active ingredient, the dimeric form of truncated envelope protein of a dengue virus serotype. The dimeric truncated E is secreted as a recombinantly produced protein from eucaryotic cells. The diagnostic may further contain portions of additional dengue virus serotype dimeric E proteins similarly produced.

1 . A vaccine for the protection of a subject against infection by a Flavivirus, wherein said vaccine comprises a therapeutically effective amount of a dimeric 80% E, said dimeric 80% E having been secreted as a recombinantly produced protein from Drosophila Schneider cells, wherein 80% E represents the N-terminal 80% portion of the protein from residue 1 to residue 395.  
     
     
         2 . The vaccine of  claim 1  wherein said dimeric 80% E is selected from the group consisting of: linked 80% E dimer; 80% E ZipperI; 80% E ZipperII; and 80% E Bundle.  
     
     
         3 . The vaccine of  claim 2  wherein the linked 80% E dimer is a truncated envelope protein of serotype DEN-1.  
     
     
         4 . The vaccine of  claim 2  wherein the linked 80% E dimer is a truncated envelope protein of serotype DEN-2.  
     
     
         5 . The vaccine of  claim 1  wherein the linked 80% E dimer is a truncated envelope protein of serotype DEN-3.  
     
     
         6 . The vaccine of  claim 1  wherein the linked 80% E dimer is a truncated envelope protein of serotype DEN-4.  
     
     
         7 . A multivalent vaccine for the protection of a subject against infection by a Flavivirus, wherein said vaccine comprises a therapeutically effective amount of a first dimeric 80% E product of one flaviviral serotype; a second dimeric 80% E product of a second flaviviral serotype; a third dimeric 80% E product of a third flaviviral serotype; and a fourth dimeric 80% E product of a fourth flaviviral serotype; wherein all dimeric 80% E products have been secreted as recombinantly produced protein from a Drosophila Schneider cell, wherein 80% E is the N-terminal 80% of the protein from residue 1 to residue 395.  
     
     
         8 . A vaccine of  claim 7  wherein said dimeric 80% E products are envelope proteins of serotypes selected from the group consisting of: DEN-1; DEN-2; DEN-3; and DEN-4.  
     
     
         9 . The vaccine of  claim 1  wherein said Flavivirus is a dengue virus.  
     
     
         10 . The vaccine of  claim 2  wherein said Flavivirus is a dengue virus.  
     
     
         11 . The vaccine of  claim 7  wherein said Flavivirus is a dengue virus.  
     
     
         12 . A method to protect a subject against a Flavivirus, which method comprises administering to a subject in need of such protection an effective amount of the vaccine of  claim 1 , wherein said 80% E is the N-terminal 80% of the protein from residue 1 to residue 395.  
     
     
         13 . A method to protect a subject against a Flavivirus, which method comprises administering to a subject in need of such protection an effective amount of the vaccine of  claim 1 , wherein said 80% E is the N-terminal 80% of the protein from residue 1 to residue 395.  
     
     
         14 . An immunogenic polypeptide comprising a dimeric 80% E, said dimeric 80% E having been secreted as a recombinantly produced protein from Drosophila Schneider cells, wherein 80% E represents the N-terminal 80% of the protein from residue 1 to residue 395.  
     
     
         15 . The immunogenic polypeptide of  claim 14  wherein said dimeric 80% E is selected from the group consisting of: linked 80% E dimer, 80% E ZipperI; 80% E ZipperII; and 80% E bundle.  
     
     
         16 . The immunogenic polypeptide of  claim 15  wherein the linked 80% E dimer is a truncated envelope protein which is at least one member selected from the group consisting of serotype DEN-1, serotype DEN-2, serotype DEN-3, and serotype DEN-4.  
     
     
         17 . An immunogenic composition for the protection of a subject against infection by Flavivirus comprising the immunogenic polypeptide defined in  claim 14  and a physiologically acceptable carrier.  
     
     
         18 . The immunogenic composition defined in  claim 17  further comprising an adjuvant.  
     
     
         19 . The immunogenic polypeptide defined in  claim 17  wherein said adjuvant is Iscomatrix.  
     
     
         20 . An immunodiagnostic for the detection of Flavivirus comprising the immunogenic polypeptide defined in  claim 14 .  
     
     
         21 . A multivalent immunodiagnostic for the detection of Flavivirus comprising at least two of the immunogenic polypeptides defined in  claim 14  of at least two flaviviral serotypes.  
     
     
         22 . A vector host recombinant DNA expression system, which comprises: 
 a) a Drosophila host cell;    b) a suitable recombinant DNA expression vector;    c) DNA encoding dimeric 80% E, operably linked and under the control of a suitable promoter; and    d) said DNA encoding dimeric 80% E operably linked to a secretory signal leader sequence,    wherein 80% E represents the N-terminal 80% portion of the protein from residue 1 to residue 395.    
     
     
         23 . The vector host recombinant DNA system of  claim 22 , wherein said dimeric 80% E is selected from the group consisting of: linked 80% E dimer; 80% E ZipperI; 80% E ZipperII; and 80% E Bundle.  
     
     
         24 . A DNA sequence encoding the immunogenic polypeptide defined in  claim 14 .  
     
     
         25 . An immunodiagnostic kit for the detection of Flavivirus in a test subject comprising 
 a) the immunogenic polypeptide defined in  claim 14;     b) a suitable support phase coated with dimeric 80% E; and    c) labeled antibodies immunoreactive to antibodies from said test subject.    
     
     
         26 . An immunodiagnostic kit for the detection of Flavivirus in a test subject comprising 
 a) the multivalent immunodiagnostic polypeptide defined in  claim 21;     b) a suitable support phase coated with dimeric 80% E; and    c) labeled antibodies immunoreactive to antibodies from said test subject.